Valion Bio's CDMO unit reports early data from LarmorBio NMR monitoring deal

Valion Bio, Inc. and LarmorBio, Inc. announced on October 15, 2026 that Velocity Bioworks, Valion's wholly owned biologics contract development and manufacturing organization subsidiary, completed an initial feasibility evaluation of LarmorBio's BioScan-NMR platform.¹ The companies said the milestone came less than six months after Valion secured exclusive rights to LarmorBio's next-generation NMR technology.¹

BioScan-NMR is intended to become a new class of process analytical technology for biologics manufacturing.¹ According to the release, the initial feasibility evaluation showed that NMR measurements have the potential to track microbial growth during a fermentation process.¹ The companies reported that the test found a close relationship between the BioScan-NMR signal and OD600, a standard method scientists use to estimate how dense a liquid cell culture is, which they said points toward the platform's ability to pick up signs of microbial growth.

Valion's interim CEO, Dean Zikria, described the project as "an early-stage proof-of-concept"¹ with results he called encouraging. He said the company hopes BioScan-NMR could eventually offer insight into factors such as the makeup of growth media, conditions inside the fermenter, and other process and product characteristics, potentially cutting down on the need for routine invasive sampling.¹

Valion said Velocity Bioworks plans to use the feasibility results to guide further work, including testing whether the system can operate as a closed, continuous monitoring tool, per the filing.

Separately, the filing reiterated that Valion's lead program, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome under the FDA's Animal Rule and has received Fast Track and Orphan Drug designations from the FDA.¹ The company is also developing Entolasta, a next-generation TLR5 agonist intended for broader uses including oncology supportive care.¹